https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html
Deal terms show about approx 100% to previous close/ 30-day VWAP, so it imperative for the SP to be considerably high otherwise the company will be bought for a song.
Fusion themselves acquired this PSMA targeting program from RadioMedix for $60Mn in Feb 2023. So it is a matter of the big fish the medium fish who swallow the small fish and krill. The dosage regimens are in the range of 25GBq to 100GBq of 225 Lutetium. In my layman’s view CU6 being able to get about 95% at one cycle of 12GBq is phenomenal and gold standard?
https://ir.fusionpharma.com/2023-02-13-Fusion-Pharmaceuticals-to-Acquire-Phase-2-Program-for-225Ac-PSMA-I-T,-a-Radiopharmaceutical-Targeting-Metastatic-Castrate-Resistant-Prostate-Cancer
I guess the market is hot and a deal is not too far in the future?
Research/Valuation, page-228
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$8.55 |
Change
-0.180(2.06%) |
Mkt cap ! $2.742B | |||
| Open | High | Low | Value | Volume |
| $8.62 | $8.68 | $8.50 | $1.064M | 124.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 115 | $8.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $8.56 | 562 | 9 |
View Market Depth
| Last trade - 11.00am 04/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |